KPV Peptide: What Lakeland Readers Should Know

KPV is a very small peptide promoted for inflammation of the gut and skin. It became one of the most discussed compounding peptides of 2026, even though it has never been studied in people. It is general information, not advice for your situation.

What it is and how it works

KPV is a chain of just three amino acids: lysine, proline and valine. It is the end piece of a natural hormone called alpha-melanocyte-stimulating hormone (alpha-MSH). It is not part of any FDA-approved drug.¹

In cell studies, KPV turned down inflammation signals. Given in drinking water to mice, it reduced chemically caused colitis (inflammation of the colon). It entered cells through a gut transporter called PepT1.² FDA notes that the molecules KPV acts on “remain unknown.”¹

What the research shows (and where evidence is weak)

There is no human research. FDA’s 2026 review found no published studies, no clinical trials and no human exposure data for KPV by any route. All of the references sent to FDA in support of KPV were animal or lab studies.¹

There is also a practical problem for creams. In a lab test, KPV did not pass through intact human skin. FDA said this could limit both its risks and how well a skin product works.¹

Mouse results often fail to carry over to people. Without any human study, no one knows whether KPV helps people, what it does in the body, or how safe it is.

FDA and regulatory status

Not approved. KPV is not FDA-approved and is not part of any approved drug.¹

FDA’s safety-concern list. KPV was on FDA’s “Category 2” list of bulk ingredients that may pose significant safety risks in compounding, because FDA found no human exposure data. By April 22, 2026, the nominations were withdrawn; FDA still lists its safety concerns.³

FDA review and advisory vote. In May 2026, FDA’s scientists recommended against adding KPV to the 503A bulks list, the list of ingredients that state-licensed pharmacies can use in compounding.¹ An FDA advisory committee narrowly voted in July 2026 to recommend adding KPV; FDA’s own reviewers had recommended against it, and the vote is not binding. The vote was reported as 8–6 with 1 abstention.⁴⁵ FDA has posted no minutes.⁶

2026 HHS draft policy. According to law-firm summaries of the draft policy, it covers six peptides: BPC-157, TB-500, KPV, MOTS-c, epitalon and semax.⁷⁸ As of 13 Nov 2026, HHS has published a draft, non-binding policy saying it does not intend to take enforcement action against licensed pharmacies compounding these peptides in certain forms.⁹ This is not FDA approval, and FDA has not added them to its official list.

The same summaries say the KPV forms named are topical and oral products. Conditions they describe include an FDA-registered ingredient source with a certificate of analysis, a single active ingredient, documented absorption in people for oral products, and a patient-specific prescription.⁷⁸ FDA found no human data on KPV at all, so it is unclear whether any oral KPV product could meet that absorption condition. As of November 13, 2026, a final policy had not been published. Check the Federal Register notice for updates.⁹

Products sold online as “research peptides” are not made or checked as medicines. See our guides to research chemical peptide risks and Florida peptide rules.

Sport. KPV is not named on WADA’s 2026 Prohibited List.¹⁰ It is likely covered by WADA’s ban on unapproved substances; athletes should check with their anti-doping organization.

Common side effects and safety

Safety in people is unknown. FDA found no studies of short-term or repeated-dose toxicity in animals, no studies of effects on genes and no cancer-risk studies. FDA said it is “particularly concerned” about the lack of any human data, including on possible immune reactions.¹

If you have used KPV and notice any symptom that worries you, tell a licensed provider.

Typical cost range

There is no reliable price data. KPV is not an approved product, so there is no official list price, and no published cost analysis was found. Prices vary between clinics and pharmacies. Ask any provider for a written price breakdown before you start.

Questions to ask a provider

• Since KPV has never been studied in people, why do you recommend it for me?
• Which state-licensed pharmacy makes it, and does it meet the current HHS policy conditions?
• For an oral product, what evidence shows the body absorbs it?
• What better-studied options should I try first?
• What side effects should I watch for, and how do I reach you?
• What is the total cost?